

Supplementary Table 3. Comparison of annual estimated glomerular filtration decline rate (mL/min/1.73m²/year) between clinical trials

Mayo imaging classification	TEMPO 3:4 trial		ESSENTIAL trial	KNOW-CKD trial
	Tolvaptan (n = 830)	Placebo (n = 447)	Tolvaptan (n = 108)	Without tolvaptan (n = 178)
1A				-1.54 (-2.30 to -0.77)
1B	-2.10 (-2.69 to -1.52)	-1.79 (-3.08 to -0.51)		-2.06 (-2.48 to -1.64)
1C	-2.32 (-2.68 to -1.95)	-3.59 (-4.18 to -3.00)	-1.22	-3.58 (-4.05 to -3.11)
1D	-2.99 (-3.34 to -2.64)	-3.89 (-4.54 to -3.24)	-3.25	-3.70 (-4.31 to -3.09)
1E	-3.46 (-4.00 to -2.92)	-4.93 (-5.87 to -3.99)	-4.47	-4.52 (-6.20 to -2.83)

Data are expressed as mean (95% CI).

ESSENTIAL, Evaluating the Safety and effectiveness in adult Korean patients treated with Tolvaptan for management of autosomal dominant polycystic kidney disease; KNOW-CKD, Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease; TEMPO 3:4, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4.